Minimal Disseminated Disease (MDD) represents the small number of tumour cells in the patients' bone marrow at the time of diagnosis, whereas Minimal Residual Disease (MRD) represents the small number of tumour cells remaining in the bone marrow during treatment. Generally, MDD and MRD are measured by polymerase chain reaction, a highly sensitive technique. For a long time, bone marrow involvement has been considered an uncommon event in solid tumours. However, in recent years, several studies demonstrated that MDD and MRD could be powerful tools in paediatric non-Hodgkin lymphoma for stratifying patients in different prognostic groups. Risk stratification in future clinical trials on non-Hodgkin lymphoma based on these newly identified ris...
The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) ha...
Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblas...
International audienceWhile outcome for pediatric T lymphoblastic lymphoma (T-LL) has improved with ...
Minimal Disseminated Disease (MDD) represents the small number of tumour cells in the patients' bone...
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatments result ...
Purpose To study minimal disseminated disease (MDD) in children with Burkitt\u2019s lymphoma (BL) an...
Risk directed treatment forms a central component of modern protocols for childhood acute lymphoblas...
Background Sensitive techniques for detection of minimal residual disease (MRD) at degrees of one le...
Background Sensitive techniques for detection of minimal residual disease (MRD) at degrees of one le...
We performed sensitive polymerase chain reaction-based minimal residual disease (MRD) analyses on bo...
The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction t...
<div><p>Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute ly...
We studied the prognostic value of minimal disseminated disease (MDD) and anti-ALK immune response i...
PURPOSE: To study the prevalence of t(8;14) at diagnosis and the response kinetics to treatment of m...
Minimal residual disease (MRD) assessment is a powerful prognostic factor for determining the risk o...
The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) ha...
Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblas...
International audienceWhile outcome for pediatric T lymphoblastic lymphoma (T-LL) has improved with ...
Minimal Disseminated Disease (MDD) represents the small number of tumour cells in the patients' bone...
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatments result ...
Purpose To study minimal disseminated disease (MDD) in children with Burkitt\u2019s lymphoma (BL) an...
Risk directed treatment forms a central component of modern protocols for childhood acute lymphoblas...
Background Sensitive techniques for detection of minimal residual disease (MRD) at degrees of one le...
Background Sensitive techniques for detection of minimal residual disease (MRD) at degrees of one le...
We performed sensitive polymerase chain reaction-based minimal residual disease (MRD) analyses on bo...
The aim of the study was to analyze the impact of minimal residual disease (MRD) after reinduction t...
<div><p>Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute ly...
We studied the prognostic value of minimal disseminated disease (MDD) and anti-ALK immune response i...
PURPOSE: To study the prevalence of t(8;14) at diagnosis and the response kinetics to treatment of m...
Minimal residual disease (MRD) assessment is a powerful prognostic factor for determining the risk o...
The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) ha...
Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblas...
International audienceWhile outcome for pediatric T lymphoblastic lymphoma (T-LL) has improved with ...